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Abstract
Vitamin D may have a protective role in insulin secretion and an effect on insulin resistance. Low
levels of vitamin D are indicated as a risk factor for both type 1 and type 2 diabetes, however, clinical
evidence that increased vitamin D levels benefit diabetic patients has not yet been established.
Introduction and context
Low levels of vitamin D may be a risk factor for the
development of both type 2 [1] and type 1 [2] diabetes.
The role of vitamin D in insulin secretion and transfer
of the insulin message in insulin sensitive tissues is
discussed. Some clinical studies on the relationship
between vitamin D levels and development of diabetes
are included.
Vitamin D and calcium
Vitamin D3, or cholecalciferol, is formed in the skin by
ultraviolet radiation. External supplementation of vita-
min D is necessary when low levels of vitamin D are
found, such as during periods with little sun, and when
the body is totally covered and the intake of vitamin D in
the diet is low. The vitamin D3 generated in the skin is
biologically not very active and has to be activated via
two enzymatic steps. First, vitamin D3 is hydroxylated to
25-hydroxycholecalciferol (25(OH)D3) in the liver by
the enzyme 25-hydroxylase. Next, 1-alpha-hydroxylase,
present primarily in the kidneys but also in other tissues,
hydroxylates 25(OH)D3 into 1,25-dihydroxycholecalci-
ferol (1,25-(OH)2D3), the hormonally active form [3].
1,25-(OH)2D3 and parathyroid hormone regulate cal-
cium homeostasis. Levels of 25(OH)D3 over 50 nmol/l
(in Europe [4]) or 70 nmol/l (in the US) are considered
sufficient; levels under 25 nmol/l are clearly deficient.
Vitamin D has two intracellular effects: it binds to the
intranuclear vitamin D receptor, which modulates gene
expression, and it has an effect through the regulation of
extracellular and intracellular calcium [5]. Moreover,
vitamin D may also reduce apoptosis of ß cells in type 2
diabetes by inhibiting inflammatory reactions [6] and
increasing calbindin, a cytosolic calcium binding
protein [7].
Calcium is important for many cellular processes and its
levels are regulated by parathyroid hormone and vitamin
D. Vitamin D increases calcium resorption in the gut
and stimulates the uptake of calcium in many tissues,
including the islets of Langerhans. Calcium has an
essential role in glucose-induced insulin secretion [8,9].
Insulin secretion from the ß cell
When glucose enters a ß cell, ATP production is increased
and the resulting high levels of ATP/ADP lead to closure
of the potassium channels in the membrane. This
increases the influx of calcium, which stimulates insulin
secretion from the ß cell. Vitamin D stimulates this
glucose-stimulated insulin secretion [10]. The ß cell has a
vitamin D receptor that binds 1,25-(OH)2D3. 1-alpha-
hydroxylase is also found inside the ß cell [11]. It is not
clear whether the effect of vitamin D is a consequence of
increased availability of intracellular calcium.
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Insulin resistance is frequently seen in type 2 diabetes
and insulin resistance in diabetes is always combined
with cellular changes in the islet cells. An important
factor for insulin resistance is obesity, in which fat
metabolism is more prominent and higher levels of free
fatty acids are seen. Mitochondria are essential for the
metabolism of fatty acids and high amounts of fatty
acids in the cell reduce the formation of ATP, which
decreases insulin secretion in the ß cell [12]. When
insulin resistance is increased in non-diabetics the ß cell
produces more insulin to prevent hyperglycemia and no
increase in glucose levels is seen. In impaired glucose
tolerance the ß cell cannot produce sufficient amounts of
insulin to keep blood glucose within normal limits.
When (genetic) factors favoring diabetes are present,
insulin resistance leads to the expression of type 2
diabetes. Insulin resistance is always combined with
cellular changes in the islet cells.
An increased extracellular supply of calcium increases the
availability of intracellular calcium, which is necessary
for insulin-mediated processes in insulin-sensitive cells
such as those of fat and muscle [13]. Vitamin D increases
the expression of insulin receptors in human-derived
cells [14]. Whether vitamin D reduces insulin resistance
directly through improvement of the insulin signaling
pathway in the cell or whether it primarily stimulates
insulin secretion is not clear. The major role of vitamin D
in insulin resistance is protection of the insulin secreting
capacity of the ß cell and suppression of peripheral
inflammation.
Metabolic syndrome
Insulin resistance is an important feature of metabolic
syndrome and obesity is an important factor for the
emergence of type 2 diabetes. Although vitamin D
facilitates insulin secretion, a causal relationship
between low vitamin D levels and the presence of
metabolic syndrome is unclear. Hypertension and
vascular disease are associated with metabolic syndrome,
and vitamin D deficiency in those with metabolic
syndrome may increase the development of cardiovas-
cular disease and increase inflammatory reactions in the
ß cell and adipose tissue.
Diabetes mellitus
In type 1 diabetes vitamin D may reduce the immuno-
logical effect on islet cell destruction and in type 2
diabetes it may improve the cellular transfer of the
insulin message. Vitamin D may also contribute to the
survival of the islets and inhibit inflammatory processes.
Some authors [15] report a relationship between
low vitamin D levels in humans and reduced glucose-
stimulated insulin secretion. In some trials improvement
of (glucose-stimulated) insulin release after vitamin D
supplementation has been found but other studies have
not confirmed this [16,17]. Most prospective studies are
short term and give variable outcomes about the
relationship between vitamin D levels and the develop-
ment of diabetes (for recent reviews on various aspects of
vitamin D and diabetes see [1,18]).
Recent advances
Associations between low vitamin D levels and meta-
bolic syndrome have been reported in British [19],
American [20,21], and Chinese patients [22]. However,
these associations do not answer the question of whether
vitamin D deficiency contributes to the emergence of the
metabolic syndrome; long-term prospective studies are
necessary to determine a potential role of vitamin D in
this syndrome.
Four studies looking at the effects of vitamin D
supplementation on glycemic status and insulin resis-
tance have been reported recently. In a 3-year study,
Pittas et al. [23] found that supplementation of calcium
and vitamin D in older people with impaired glucose
tolerance reduced the rise of fasting glucose and insulin
resistance when compared with non-supplemented
patients. A long-term prospective study over 10 years
found inverse relations between baseline 25(OH)
vitamin D and future hyperglycemia and insulin
resistance [24]. However, when serum 25(OH) vitamin
D was increased from 39.9 ± 1.5 (standard error of the
mean) to 90.3 ± 4.3 nmol/l (P < 0.0001) by adminis-
trationofmore vitaminD,nochangewasobservedinmean
blood glucose or insulin levels 0-120 minutes after
glucose was given, and no change in insulin sensitivity
was seen [25]. Half of 33,951 postmenopausal women
in the Women’s Health Initiative received 400 IE (10 µg)
vitamin D per day for 7 years. Although this treatment
did not reduce the development of diabetes [26], 10 µg
daily is a low supplementary dose.
As mentioned above, hypertension and vascular disease
are associated with metabolic syndrome. In the Framing-
ham Offspring Study, 28% of 1,739 participants with no
cardiovascular disease had a 25(OH)D3 level under
15 ng/ml (39 nmol/l) and after 5.4 years 120 partici-
pants developed cardiovascular disease. Those with low
25(OH)D3 levels were 1.62 times more likely to develop
vascular disease and when a low 25(OH)D3 level was
combined with high blood pressure, the chance
increased to 2.13; this difference was significant [27].
No direct clinical data are available on the relationship
between vitamin D deficiency and the emergence of type
Page 2 of 4
(page number not for citation purposes)
F1000 Medicine Reports 2009, 1:85 http://F1000.com/Reports/Medicine/content/1/851 diabetes, but the observation that 1,25-(OH)2D3
prevents diabetes mellitus in animal models highlights
a potential association. Vitamin D deficiency modifies T
cell differentiation and induces cytokine secretion and
stimulates dendritic cells, which facilitate the autoim-
mune destruction of ß cells. Therefore, low levels of
vitamin D could make people more susceptible to type 1
diabetes [2]. Also, low vitamin D levels during pregnancy
may increase the incidence of autoimmune diseases such
as type 1 diabetes in children [2].
In type 2 diabetes, insulin resistance plays an important
role (see above). In islet cells of persons with type 2
diabetes, signs of inflammation can be seen. Adipose
tissue in (obese) persons with type 2 diabetes also
displays signs of inflammation, contributing to insulin
resistance [28]. Vitamin D inhibits the release and down-
regulates increased levels of inflammatory markers such
as interleukin (IL)-6, IL-1, and IL-8, intracellular adhe-
sion molecule-1, and cyclo-oxygenase-2 [6]. This may
contribute both to the positive effect of vitamin D on
islet cells and the reduction of elevated C-protein levels,
an indication of (vascular) inflammatory processes in
type 2 diabetes.
Implications for clinical practice
Vitamin D improves insulin secretion and reduces
insulin resistance. Low vitamin D levels contribute to
the manifestation of diabetes mellitus and a more rapid
increase of insulin deficiency. Moreover, increased
vitamin D levels may prevent the immunological process
that destroys ß cells in type 1 diabetes and may reduce
the inflammatory processes in the ß cell and the
periphery and contribute to improved insulin signal
transfer in type 2 diabetes.
It is not clear what levels of vitamin D are sufficient. It
may be that levels of vitamin D within the normal range
for an effect on bone formation and calcium metabolism
are too low to reduce the emergence of diabetes mellitus
and to improve glucose homeostasis, but a clear
minimum level of 25(OH)D3 needed for slowing the
development of diabetes mellitus has not been estab-
lished. The prescription of extra vitamin D during the
early phase of diabetes is still experimental and more
long-term clinical studies are necessary to gain better
insight into the role of vitamin D and to establish what
levels of vitamin D are optimal to reduce the emergence
of diabetes. Currently, it has not been established
whether it is useful to estimate vitamin D levels or
prescribe vitamin D when diabetes mellitus is diagnosed
except for investigational purposes. In conclusion, there
is not yet sufficient evidence that administration of
vitamin D will improve diabetes.
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